Framler
Signal Feed
WatchlistTrack Record
⌕
LIVE
Framler · © 2026
Engine
MethodologySectorsPatternsCompareAlternativesScreenersGlossaryTrack RecordSleeve P&LShort SqueezeTop Rated
Research moat
MoatResearchCase Study: NVDA
Company
InvestorsPressBlogChangelogRoadmapAPIAboutContact
FEATURED ANALYSISNVDATSLAAAPLAMDMSFTMETA
Framler is a quantitative research platform - not a broker, investment advisor, or fiduciary. Nothing on this site constitutes a recommendation to buy, sell, or hold any security. All model outputs - scores, verdicts, intervals, predictions - are for informational and educational purposes only. Past performance does not guarantee future results. Invest at your own risk. Built on public data - SEC EDGAR, ClinicalTrials.gov, PubMed, Yahoo Finance, Finnhub, FMP.
TRUSTThe BetLedgerStatusSecurity·LEGALTermsPrivacyDisclaimer
Intellia Therapeutics (NTLA) company logo
Healthcare · NASDAQ
Calibration 4/4:●1d●7d●30d●90d

NTLA STOCK · Intellia Therapeutics NeutralMulti-factor aligned

$12.44-6.33%
~1-month outlook, not a day-trade. The score updates daily as the data changes — re-check weekly rather than reacting to a single day's move.
48
◐Sector calibration · noisy
Engine accuracy in Healthcare has been close to zero on recent rolling windows. Treat the composite as informational. Lean on Confluence patterns, Insider clustering, and Options flow — sub-signals that retain edge in narrative-driven cohorts.
AgreementMODERATE ALIGNMENT

Some factor streams agree, others diverge.

90% interval: [5–95]Top driver: Sector Spillover
OutlookMiddle of universe — weak directional signal this week🔒 Sign in for number

Why NTLA scores 48

  • +Sector in favour — rotation tailwind
  • +Adjacent industry leaders rallying (Cohen-Frazzini)
  • -Quality metrics weak — margins or leverage flagged

Full report — sign in to unlock

🧬 Phase 3 / FDA catalyst

NTLA has an active Phase 3 clinical trial — NCT06672237. Framler models the failure probability for NTLA from ClinicalTrials.gov data — the figure is shown after you sign in.

🧬 Biotech intelligence
Bayesian Phase-3 trial failure probability vs the disease base rate, an estimated FDA decision window, patent-cliff timing, and comparable historical trials — the biotech layer for NTLA.
🔒 Sign up to unlock →
🔒 Forward-Return Projection

Expected returns over 1 / 7 / 30 / 90 days with 90% confidence intervals, regime amplifier, pattern multiplier, copula tail-dependence — composed into one Bayesian distribution.

🔒 Full Factor Breakdown

Per-factor 0-100 scores across quality, value, momentum, PEAD, accruals, insider flow, NLP tone, options flow, short interest, sector momentum, factor interaction — plus the score waterfall.

🔒 Confluence Patterns

Active multi-factor patterns (QUALITY COMPOUNDER, VALUE TRAP, SHORT SQUEEZE, OVEREXTENDED, etc.) with academic basis and pattern delta against the raw composite.

🔒 Plain-English Explanation & Scenarios

Plain-English read of what the engine sees on this ticker today + what-if scenarios (price ±N%, regime flip, shock) replayed through the deterministic engine. No AI in the scoring path.

Unlock the full NTLA report
Free during early access · no credit card · 1,000+ stocks tracked daily
Sign up free →
How is this score built?Methodology →24 patterns →Research paper →Sector rotation →Track record →Glossary →Math coherence →

Were we right on NTLA? — 72 graded days

WE MADE A CALL ON 22 OF 72 DAYS — RIGHT 14 · WRONG 8
-30%-25%-20%-15%-10%-5%0%+5%+10%+15%+20%
factor
🔒 Insider Flow & News Grid

90-day net SEC Form 4 dollar flow with size normalisation, plus filtered news headlines clustered by topic.

🔒 Watchlist & Virtual Trades

Add to watchlist for daily score alerts; place a paper trade with the engine's confidence dial frozen at entry; track P&L over 30 / 90 / 180 days against the verdict horizon.

+25%+30%2026-05-05: no call (score 44) — stock went +5.11% over the next 7 days2026-05-06: no call (score 44) — stock went +7.29% over the next 7 days2026-05-07: no call (score 53) — stock went -5.49% over the next 7 days2026-05-08: no call (score 55) — stock went -0.29% over the next 7 days2026-05-11: no call (score 53) — stock went -16.98% over the next 7 days2026-05-12: no call (score 53) — stock went -17.20% over the next 7 days2026-05-13: no call (score 47) — stock went -13.96% over the next 7 days2026-05-14: no call (score 47) — stock went -13.38% over the next 7 days2026-05-15: no call (score 45) — stock went -3.74% over the next 7 days2026-05-18: no call (score 41) — stock went -7.75% over the next 7 days2026-05-19: we said UP (score 89), stock went -0.63% over the next 7 days — WRONG2026-05-20: no call (score 45) — stock went +12.56% over the next 7 days2026-05-21: no call (score 44) — stock went +11.58% over the next 7 days2026-05-22: no call (score 51) — stock went +13.74% over the next 7 days2026-05-25: no call (score 48) — stock went +8.97% over the next 7 days2026-05-26: no call (score 48) — stock went +4.21% over the next 7 days2026-05-27: no call (score 47) — stock went +3.25% over the next 7 days2026-05-28: we said UP (score 78), stock went +9.75% over the next 7 days — RIGHT2026-05-29: we said UP (score 86), stock went -1.02% over the next 7 days — WRONG2026-06-01: we said UP (score 87), stock went -4.12% over the next 7 days — WRONG2026-06-02: we said UP (score 75), stock went -6.12% over the next 7 days — WRONG2026-06-03: no call (score 42) — stock went -7.08% over the next 7 days2026-06-04: no call (score 42) — stock went -5.15% over the next 7 days2026-06-05: no call (score 48) — stock went -17.90% over the next 7 days2026-06-08: we said UP (score 85), stock went +10.19% over the next 7 days — RIGHT2026-06-09: no call (score 41) — stock went +7.86% over the next 7 days2026-06-10: no call (score 45) — stock went +17.92% over the next 7 days2026-06-11: no call (score 47) — stock went +28.44% over the next 7 days2026-06-12: we said DOWN (score 40), stock went +27.53% over the next 7 days — WRONG2026-06-15: no call (score 52) — stock went +30.06% over the next 7 days2026-06-16: no call (score 44) — stock went +2.21% over the next 7 days2026-06-17: no call (score 47) — stock went +6.53% over the next 7 days2026-06-18: we said UP (score 70), stock went +5.46% over the next 7 days — RIGHT2026-06-19: we said UP (score 72), stock went +6.45% over the next 7 days — RIGHT2026-06-22: we said UP (score 73), stock went +6.00% over the next 7 days — RIGHT2026-06-23: we said UP (score 71), stock went +7.43% over the next 7 days — RIGHT2026-06-24: we said UP (score 70), stock went +13.05% over the next 7 days — RIGHT2026-06-25: no call (score 46) — stock went +13.29% over the next 7 days2026-06-26: no call (score 50) — stock went +11.29% over the next 7 days2026-06-29: we said UP (score 88), stock went +6.95% over the next 7 days — RIGHT2026-06-30: we said UP (score 86), stock went +4.94% over the next 7 days — RIGHT2026-07-01: we said UP (score 74), stock went -0.47% over the next 7 days — WRONG2026-07-02: we said UP (score 71), stock went -10.44% over the next 7 days — WRONG2026-07-03: no call (score 46) — stock went -19.05% over the next 7 days2026-07-06: no call (score 47) — stock went -25.85% over the next 7 days2026-07-07: no call (score 49) — stock went -25.45% over the next 7 days2026-07-08: no call (score 44) — stock went -24.18% over the next 7 days2026-07-09: no call (score 47) — stock went -29.57% over the next 7 days2026-07-10: no call (score 43) — stock went -26.33% over the next 7 days2026-07-13: we said DOWN (score 40), stock went -23.18% over the next 7 days — RIGHT2026-07-14: we said DOWN (score 38), stock went -11.90% over the next 7 days — RIGHT2026-07-15: no call (score 41) — stock went -16.32% over the next 7 days2026-07-16: no call (score 44) — stock went -14.88% over the next 7 days2026-07-17: no call (score 42) — stock went -9.53% over the next 7 days2026-07-20: no call (score 42) — stock went -6.20% over the next 7 days2026-07-21: we said DOWN (score 38), stock went -0.27% over the next 7 days — RIGHT2026-07-22: no call (score 47) — stock went -5.84% over the next 7 days2026-07-23: no call (score 46) — stock went -0.36% over the next 7 days2026-07-24: no call (score 46) — stock went -3.78% over the next 7 days2026-07-27: no call (score 46) — stock went +0.37% over the next 7 days2026-07-28: no call (score 43) — stock went +6.09% over the next 7 days2026-07-29: no call (score 50) — stock went +0.73% over the next 7 days2026-07-30: no call (score 44) — stock went +4.07% over the next 7 days2026-07-31: no call (score 44) — stock went +7.66% over the next 7 days2026-08-03: no call (score 44) — stock went +12.55% over the next 7 days2026-08-04: no call (score 48) — stock went +11.61% over the next 7 days2026-08-05: no call (score 49) — stock went +6.80% over the next 7 days2026-08-06: no call (score 45) — stock went +7.84% over the next 7 days2026-08-07: no call (score 44) — stock went +5.96% over the next 7 days2026-08-10: we said UP (score 75), stock went +1.26% over the next 7 days — RIGHT2026-08-11: we said UP (score 67), stock went -3.49% over the next 7 days — WRONG2026-08-12: we said UP (score 70), stock went +10.48% over the next 7 days — RIGHTMay 5Aug 12
we made a call and were rightwe made a call and were wrongno call that day

Each bar is what NTLA actually did over the 7 days after one of our published scores — up bars, the stock rose; down bars, it fell. A “call” is a day the score left the middle zone (above 60 = we said up, below 40 = we said down), and it's counted right only if the stock then moved our way. Faint bars are days we made no call — saying “we don't know” is allowed here. These are raw counts on one stock, far too few to prove skill either way — the serious, pre-registered test across all 1,001 stocks is the public bet.